Skip to main content

Advertisement

SpringerLink
Log in

Is everolimus linked to metabolic syndrome in liver transplant recipients?

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

As the mortality rates after liver transplantation (LT) have been reduced, the attention has shifted to additional conditions which still compromise the quality of life and the survival of these patients, such as the post-LT metabolic syndrome (MS). In order to determine the prevalence and the factors associated with the post-LT MS, we carried out the present study.

Methods

One hundred and six LT recipients, after completing at least 1 year follow up after LT, were included in the study. Data on clinical, laboratory parameters and immunosuppressive therapy before and after LT were recorded. MS was defined as per current diagnostic criteria.

Results

MS was prevalent in 47.2% (50 of 106 patients) and was not associated with the LT indications and the time period after LT. Univariate analysis showed that history of diabetes mellitus before (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.046–9.918, p = 0.042) and after LT (OR 6.03, 95% CI 2.18–16.67, p = 0.001), the age at the time of baseline visit (OR 1.077, 95% CI 1.033–1.124, p = 0.001) and the everolimus-based immunosuppression (OR 1.23, 95% CI 1.003–1.33, p = 0.019) were significantly associated with MS. Notably, everolimus administration was the only factor independently associated with the presence of post-LT MS (OR 1.026, 95% CI 1.004–1.047, p = 0.019). More specifically, everolimus was linked to the presence of arterial hypertension (OR 1.02, 95% CI 1.0–1.03, p = 0.05) and hyperlipidemia (OR 2.87, 95% CI 1.28–6.56, p = 0.011).

Conclusions

Our study demonstrated for the first time that everolimus was independently associated with post-LT MS. Nevertheless, more robust studies are required to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Mare-Bredemeijer EL, Metselaar HJ. Optimization of the use of calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:85–95.

    Article  Google Scholar 

  2. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497–503.

    Article  Google Scholar 

  3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.

    Article  CAS  Google Scholar 

  4. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation. 2012;94:659–68.

    Article  CAS  Google Scholar 

  5. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.

    Article  CAS  Google Scholar 

  6. Satapathy SK, Charlton MR. Posttransplant metabolic syndrome: new evidence of an epidemic and recommendations for management. Liver Transpl. 2011;17:1–6.

    Article  Google Scholar 

  7. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben AZ. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17:15–22.

    Article  Google Scholar 

  8. Thoefner LB, Rostved AA, Pommergaard HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: a systematic review and metaanalysis. Transplant Rev (Orlando). 2018;32:69–77.

    Article  Google Scholar 

  9. Madhwal S, Atreja A, Albeldawi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012;18:1140–6.

    Article  Google Scholar 

  10. Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

  11. Αmerican Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9.

    Article  Google Scholar 

  12. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.

  13. Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.

    Article  Google Scholar 

  14. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008;14:1648–54.

    Article  Google Scholar 

  15. Jiménez-Pérez M, González-Grande R, Omonte Guzmán E, Amo Trillo V, Rodrigo López JM. Metabolic complications in liver transplant recipients. World J Gastroenterol. 2016;22:6416–23.

    Article  Google Scholar 

  16. Durand F. How to improve long-term outcome after liver transplantation? Liver Int. 2018;38 Suppl 1:134–8.

    Article  Google Scholar 

  17. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant. 2012;12:1855–65.

    Article  CAS  Google Scholar 

  18. De Simone P, Fagiuoli S, Cescon M, et al. Use of everolimus in liver transplantation: recommendations from a working group. Transplantation. 2017;101:239–51.

    Article  Google Scholar 

  19. Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101:2873–82.

    Article  CAS  Google Scholar 

  20. Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

    Εvangelos Cholongitas, Argyro Koukoufiki & Ioannis Goulis

  2. First Department of Internal Medicine, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Agiou Thoma 17, 115 27, Athens, Greece

    Εvangelos Cholongitas

  3. Renal Clinical Fellow, Queen Elizabeth University Hospital, Glasgow, UK

    Chrysoula Pipili

  4. Department of Transplant Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Nikolaos Antoniadis & Ioannis Fouzas

  5. Department of Hygiene and Epidemiology, Medical School of Aristotle University of Thessaloniki, Thessaloniki, Greece

    Anna-Bettina Haidich

Authors
  1. Εvangelos Cholongitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyro Koukoufiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chrysoula Pipili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikolaos Antoniadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ioannis Fouzas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna-Bettina Haidich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ioannis Goulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Εvangelos Cholongitas.

Ethics declarations

Conflict of interest

EC,AK, CP, NA,IF, A-BH, and IG declare that they have no conflict of interest.

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was not supported by external institution or agency. Informed consent was obtained from all individual participants included in the study.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cholongitas, Ε., Koukoufiki, A., Pipili, C. et al. Is everolimus linked to metabolic syndrome in liver transplant recipients?. Indian J Gastroenterol 38, 348–355 (2019). https://doi.org/10.1007/s12664-019-00971-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-019-00971-6

Keywords

Search

Navigation